There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small ...

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

This year in review of 2024 milestones in non–small cell lung cancer (NSCLC) features coverage of the LAURA trial presented in June at the American Society of Clinical Oncology meeting in ...

New research highlights the promise of a novel stem cell treatment strategy for leptomeningeal brain metastasis (LBM), a severe form of metastatic brain cancer that spreads to membranes surrounding ...

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer. Lung cancer is the commonest cancer ...

Bob Uecker's cause of death has not been revealed, but his family said he had been battling small cell lung cancer since early 2023.

SMP-3124 is under clinical development by Sumitomo Pharma and currently in Phase II for Non-Small Cell Lung Cancer.

The Wisconsin Cancer Collaborative has published its most recent data about the number of lung cancer cases in Wisconsin.

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all cases. It develops when abnormal lung cells grow uncontrollably, forming a tumor.